Brought to you by 
Menarini markets Vanguard's frovatriptan in Europe
20 Aug 2020
Executive Summary
Private Italian pharmaceutical company Menarini will market Vanguard Medica's frovatriptan in Europe. The drug, a 5HT 1B/1D agonist, is used to treat migraine headaches.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Menarini markets Vanguard's frovatriptan in Europe
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice